Compare KT & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KT | TECH |
|---|---|---|
| Founded | 1981 | 1976 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 8.6B |
| IPO Year | 2002 | 1995 |
| Metric | KT | TECH |
|---|---|---|
| Price | $21.18 | $48.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $71.82 |
| AVG Volume (30 Days) | 919.2K | ★ 2.5M |
| Earning Date | 06-16-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.42% | 0.62% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.81 |
| Revenue | N/A | ★ $1,219,635,000.00 |
| Revenue This Year | $0.09 | $2.49 |
| Revenue Next Year | $2.13 | $6.40 |
| P/E Ratio | ★ $15.73 | $62.06 |
| Revenue Growth | N/A | ★ 5.23 |
| 52 Week Low | $17.54 | $45.12 |
| 52 Week High | $24.58 | $72.16 |
| Indicator | KT | TECH |
|---|---|---|
| Relative Strength Index (RSI) | 42.08 | 39.29 |
| Support Level | $21.12 | N/A |
| Resistance Level | $21.29 | $60.88 |
| Average True Range (ATR) | 0.31 | 3.59 |
| MACD | -0.06 | -0.80 |
| Stochastic Oscillator | 17.80 | 18.47 |
KT is South Korea's largest fixed-line telecom operator, with around 11.5 million fixed-line broadband customers and 9.5 million IPTV customers, and is the second-largest wireless operator with 28 million subscribers. Additionally, it has a number of nontelecom businesses, including real estate, payment processing, artificial intelligence, and IDC/cloud services, many of which are the focus of its growth strategy. The company was formed from the previously government-owned, monopoly telecom business and was listed in 1998. After selling its mobile business in 1994 (forming its mobile competitor, SK Telecom), KT created its own mobile operator in 1997.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.